(Total Views: 615)
Posted On: 06/07/2022 11:02:35 PM
Post# of 148878
- GSKs dostarlimab - complete remission of colorectal cancer in trial of 14 patients - great news. minimal side effects even better.
- another ASCO announcement
astrazeneca's enhertu greatly improves survival to 23.9 months for HER2low breast cancer patients, but with serious side effects. serious blood disorders, lung injuries, and 3 deaths. not good but patient overall living much longer. still, with these side effects the progress is taken seriously.
this bodes well for leronlimab, as dostarlimab being a mab promotes other mabs. another mab with minimal side effects. a trend. plus a tiny group of 14 patients taken as quality data. cytodyn constantly criticized for too small trial sizes. our ASCO poster should be taken seriously also. enhertu praised for extended survival, as it should. leronlimab is extending survival also. by a lot. with no side effects. love that.
- another ASCO announcement
astrazeneca's enhertu greatly improves survival to 23.9 months for HER2low breast cancer patients, but with serious side effects. serious blood disorders, lung injuries, and 3 deaths. not good but patient overall living much longer. still, with these side effects the progress is taken seriously.
this bodes well for leronlimab, as dostarlimab being a mab promotes other mabs. another mab with minimal side effects. a trend. plus a tiny group of 14 patients taken as quality data. cytodyn constantly criticized for too small trial sizes. our ASCO poster should be taken seriously also. enhertu praised for extended survival, as it should. leronlimab is extending survival also. by a lot. with no side effects. love that.
(2)
(0)Scroll down for more posts ▼
